Effectiveness and Tolerability of Fitostimoline Plus Cream and Gauze vs Connettivina Bio Plus Cream and Gauze

NCT ID: NCT04596124

Last Updated: 2022-07-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

116 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-18

Study Completion Date

2022-09-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to compare the efficacy and clinical tolerability of two medical devices in gauze and cream containing the aqueous extract of triticum vulgare and polyhexanide in comparison with two medical devices containing hyaluronic acid and silver sulfadiazine in the treatment of acute skin lesions . The reason why the two types of devices are compared is because hyaluronic acid and silver sulfadiazine represent the gold standard for the treatment of acute skin lesions. Therefore, making a comparison between the activity of the aqueous extract of triticum vulgare and polyhexanide and this gold standard of control in the treatment of acute skin lesions, is useful to better define the efficacy and tolerability of both medical devices in order to eventually expand the therapeutic armamentarium available for the treatment of acute skin lesions

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Skin lesions, more or less deep, are areas of rupture and tissue loss with exposure of the underlying tissues.

The term "external lesion" or "wound" indicates the morphological and functional destruction of the continuity of the superficial skin layers and, in the most serious cases, of the deep subcutaneous layers.

The lesions are evaluated and cataloged on the basis of their width, depth and characteristics. Furthermore, the development, the causes (etiopathogenesis) and the pathophysiological context of the wound are considered.

Superficial, slight lesions affect only the epidermis, the dermis and at most part of the hypodermis; the deeper ones involve all the subcutaneous tissue (fat) up to the muscles, the periosteum, reaching the exposure of the bone or supporting structures (tendons and cartilages); the most severe (chronic) are characterized by loss of substance in the skin and a poor tendency to healing.

According to the timing of healing, the lesions are divided into acute and chronic.

Acute injuries heal through 3 different phases and reach tissue repair within 8/10 weeks. Beyond this time the lesion becomes chronic and, if not acted correctly, the wound becomes more complicated and degrades in increasingly serious stages / degrees.

The acute wounds that the healthcare professional must treat most frequently are surgical wounds. Depending on their extent, acute wounds can be distinguished into stab wounds, puncture wounds, lacerated wounds and lacerated-contused wounds.

This type of acute wounds can generally heal in a physiological way or be induced to healing through the use of dressings, which reduce healing times.

The main dressings used to treat these lesions are hyaluronic acid-based dressings containing antiseptics, such as silver sulphadiazine to prevent the risk of contamination and colonization by microorganisms. In these dressings, hyaluronic acid promotes the acceleration of the tissue repair process.

However, among the main products used by hospital and non-hospital surgeries there are also dressings based on Rigenase® (aqueous extract of triticum vulgare) and polyhexanide. Rigenase®, containing the aqueous extract of triticum vulgare, has pro-proliferative, anti-inflammatory and antioxidant activity. These activities are attested by recent literature which indicates that the aqueous extract of triticum vulgare has pro-proliferative activity on fibroblasts and keratinocytes, the main cells involved in proliferation during the lesion repair process; in addition, the aqueous extract of triticum vulgare also has a documented anti-inflammatory activity, mediated by the reduction of the main cytokines responsible for skin inflammation, and an anti-metalloprotease9 activity, the main actor of inflammation in skin lesions. The antioxidant activity of Rigenase®, verified on the hemolysis of erythrocytes, is comparable to that of ascorbic acid.

The activity of polyhexanide is also fundamental for the prevention of the risk of colonization and contamination by microorganisms in acute skin lesions. In fact, this latest generation antiseptic has a consolidated antiseptic activity on gram positive and gram negative bacteria, on fungi and on some viruses, without the development of resistance both in vitro and in vivo.

Based on the foregoing, this study aims to compare the efficacy and clinical tolerability of two medical devices in gauze and cream containing the aqueous extract of triticum vulgare and polyhexanide in comparison with two medical devices containing hyaluronic acid and silver sulfadiazine. in the treatment of acute skin lesions. The reason why the two types of devices are compared is because hyaluronic acid and silver sulfadiazine represent the gold standard for the treatment of acute skin lesions. Therefore, making a comparison between the activity of the aqueous extract of triticum vulgare and polyhexanide and this gold standard of control in the treatment of acute skin lesions, is useful to better define the efficacy and tolerability of both medical devices in order to to possibly expand the therapeutic armamentarium available for the treatment of acute skin lesions

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wound Heal Wound Infection Wounds and Injuries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized, controlled, multicentric study
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

fitostimoline plus cream

Group Type EXPERIMENTAL

fitostimoline plus

Intervention Type DEVICE

randomized controlled multicentric study

fitostimoline plus gauze

Group Type EXPERIMENTAL

fitostimoline plus

Intervention Type DEVICE

randomized controlled multicentric study

connettivina bio plus cream

Group Type ACTIVE_COMPARATOR

fitostimoline plus

Intervention Type DEVICE

randomized controlled multicentric study

connettivina bio plus gauze

Group Type ACTIVE_COMPARATOR

fitostimoline plus

Intervention Type DEVICE

randomized controlled multicentric study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fitostimoline plus

randomized controlled multicentric study

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

connettivina bio plus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Outpatient patients (regardless of sex) aged 18 and over;
* Presence of acute injury
* Willingness to cooperate and ability to understand the procedures and purposes of the study;
* Willingness to take part in the study and to adhere to the experimental procedures certified by signing the written informed consent

Exclusion Criteria

* Pregnancy or breastfeeding;
* Inadequate contraceptive procedures in fertile women;
* Anamnestic data of any local and / or systemic pathology potentially able to interfere with the study parameters;
* Chronic concomitant treatment with local antiseptics, anti-inflammatory drugs (steroid and non-steroidal), analgesic, antineoplastic, immunosuppressive drugs;
* Immunodeficiency states (eg HIV infection); neoplastic diseases in progress;
* Non-therapeutic use of psychoactive substances;
* Abuse of drugs and / or alcohol;
* Neurological disorders or psychiatric conditions that may affect the validity of the consent and / or compromise the patient's adherence to the study procedures;
* Allergy, hypersensitivity or intolerance known to the constituents of the preparations under study;
* Any condition, medical or otherwise, that could significantly reduce the possibility of obtaining reliable data, achieve the objectives of the study, refine the completion of this;
* Presumption of poor reliability or collaboration;
* Treatment with any investigational drug in the last 30 days prior to the start of the study;
* Patients already enrolled in this study;
* Center staff directly involved in the management of the study and close relatives of that.
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Farmaceutici Damor Spa

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

carmine alfano

PROFESSOR

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

carmine alfano

Role: PRINCIPAL_INVESTIGATOR

università di salerno

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Barbara Maglione

Monza, MB, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

barbara maglione

Role: CONTACT

+393343293357 ext. +393343293357

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

barbara maglione

Role: primary

+393343293357 ext. +393343293357

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Fitostimoline plus

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

HM242-Solution vs Comparator
NCT04902612 UNKNOWN NA